Dengue Virus Diagnostic Tests Market of the Future and Options Evaluation Upto 2026



Dengue is a viral infectious disease that is transmitted against mosquitoes and affects humans and animals. It causes a dengue virus that belongs to the flaviviridae family and the flavivirus genus. Dengue is usually transmitted from one person to another through the bite of infected aedes aegypti mosquitoes. The symptoms of this disease are high fever, fatigue, headache, diarrhea, muscle pain, skin rashes, anemia and vomiting. Severe fever can cause epileptic seizures, yellow skin, coma or death. Dengue is caused by manifestations of the central nervous system, which include abnormal neurological signs, degree of weakness of consciousness, glowing and generalized convulsions, and delirium. The causes of neurological manifestations in the dengue are due to high quality fever. There are several tests available on the market to confirm the diagnosis, including the detection of antibodies to the virus or its RNA. Dengue management is a challenge that needs to be addressed. There are various causes that form the basis of the clinical dengue event, which requires a multimodal and effective treatment approach.

Report Review @ https://www.transparencymarketresearch.com/dengue-virus-diagnostic-tests-market.html

It is expected that the global market for diagnostic tests for the virus virus virus of the dead will significantly increase due to an increase in the incidence of dengue fever. According to the WHO (World Health Organization), the number of people with dengue increased from 2.2 million in 2010 to 3.2 million in 2015. The actual figure is still unknown. According to data published by Bhatt and associates, annually about 390 million dengue patients every year around the world, this number is constantly increasing. In America alone, there were only 2.35 million dengue patients, of which 10 200 were detected as severe fever, resulting in 1,181 fatalities in 2015. Dengue is a viral disease affecting people in Europe, South America and Asia. In the world, a large number of patients with chills were reported in the course of 2015, while in Malaysia there were more than 111,000 dengue cases and over 169,000 cases in the Philippines. This was an incredible 16% and 59.5% more than in comparison with the comparison in 2014. However, the low level of awareness in emerging countries and the high level of diagnostics are currently limiting the market. It is expected that raising awareness of the symptoms of dengue fever and increasing government initiatives to provide better healthcare institutions will provide many opportunities for the market.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43634

The market for global dengue virus diagnostic tests can be divided by species, end-user and region. Based on the type, the market for dengue virus diagnostic tests can be further classified in the biomarker test, rapid molecular testing, the IsoAmp test, and others. In terms of the end user, the market for diagnostic tests of the dengue virus can be classified into hospitals, research institutes and others. Regarding the region, the market for dengue virus diagnostic tests can be divided into North America, Europe, Latin America, the Asia Pacific and the Middle East, and Africa. Each region is divided into certain countries, such as the USA, Canada, Germany, the United States, Brazil, China, India, Japan and the GCC countries. In 2017, North America dominated the world market for diagnostic tests for Dengue Virus Viruses. Asia-Pacific and Latin American markets are emerging regions on the market. It is expected that the market in the regions will rapidly increase over the estimated period from 2018 to 2026. Strong dissemination in these regions is the result of an increased incidence of dengue, expansion in the healthcare industry, and an increase in government investment in the development of healthcare infrastructure.

The key players working on the worldwide market for diagnostic tests for the dengue virus are Arkray Inc., Ceres Nanosciences Inc., F. Hoffmann-La Roche Ltd, FK-Biotecnologia SA, Corgenix Medical Corp., QuantuMDx Group Ltd., Quidel Corp., Sansure Biotech Inc., Whidiag SAS, Pictor Ltd. and other respectable players. In order to gain competitive advantage in the industry, the main actors are actively involved in various expansion strategies. Cooperation, partnerships, agreements and presentations of new products are some of the important strategies used by market participants.


Source link